578 related articles for article (PubMed ID: 15139047)
1. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
2. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Krystal GW
Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
[TBL] [Abstract][Full Text] [Related]
4. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
6. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
7. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
8. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
9. Current treatment approaches for chronic myelogenous leukemia.
Druker BJ
Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
[TBL] [Abstract][Full Text] [Related]
10. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
12. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
13. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
14. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction inhibitors (STI571): molecularly targeted therapy.
Corujo Y; Cáceres W
P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
[TBL] [Abstract][Full Text] [Related]
17. [Clinical studies with imatinib in 2004].
Eckhardt S
Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
[TBL] [Abstract][Full Text] [Related]
18. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
19. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
20. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
Tauchi T; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
